Literature DB >> 9310634

Early stopping of trials.

A Langer.   

Abstract

Keywords:  Biomedical and Behavioral Research; Hoechst Marion Roussel; Liposome Co.; Pfizer Ltd.; Prospective Reinfarction Outcomes in the Thrombolytic Era Cardizem CD Trial (PROTECT)

Mesh：

Substances：

Year:  1997        PMID： 9310634     DOI： 10.1016/S0140-6736(05)62078-8

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

Review 1.  Premature discontinuation of clinical trial for reasons not related to efficacy, safety, or feasibility.

Authors:  M Lièvre; J Ménard; E Bruckert; J Cogneau; F Delahaye; P Giral; E Leitersdorf; G Luc; L Masana; P Moulin; P Passa; D Pouchain; G Siest
Journal:  BMJ       Date:  2001-03-10

Review 2.  Stopping trials early for commercial reasons: the risk-benefit relationship as a moral compass.

Authors:  A S Iltis
Journal:  J Med Ethics       Date:  2005-07       Impact factor: 2.903

3.  Implications of product withdrawal on a post-approval pragmatic trial: The VOLUME study experience.

Authors:  Francesca M Kolitsopoulos; Nicolle M Gatto; Kevin Sweetland; Michael B Bracken; Neville Jackson
Journal:  Contemp Clin Trials Commun       Date:  2019-10-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.